Long-Term Survival and Risk of Second Malignant Neoplasms Among Childhood Cancer Patients in 16 Provinces of Spain Authors: Jaume Galceran, Alberto Ameijide, Noura Jeghalef, Antonia Sánchez, Marcela Guevara, Jàmnica Bigorra, Pilar Gutiérrez, An L. D. Boone, Montserrat Garrido, Xitama Álvarez, Ana Vizcaíno, Isabel Martín, Amaia Onaindia, Silvia Sanclemente, Jan Trallero, María José Sánchez, María-Isabel Palacios, Ramon Clèries, Marià Carulla, on behalf of the Spanish Network of Cancer Registries (REDECAN) Published: 2026 ABSTRACT Simple SummaryChildhood cancer survival has improved substantially in recent decades; however, survivors remain at increased risk of developing cancer later in life, largely due to treatments received during childhood. This study provides the first population-based analysis in Spain, to (1) evaluate recent trends in childhood cancer survival by tumor type and (2) quantify the short- and medium-term risk of developing second malignant neoplasms (SMNs) according to time since diagnosis and tumor type. Our findings provide valuable evidence to inform strategies aimed at improving survival, reducing long-term treatment-related toxicity, and optimizing long-term follow-up care for survivors. 1. Introduction Childhood cancer survival rates have increased substantially in recent decades largely due to improvements in treatment [1,2]. Currently, five-year survival rates exceed 80% in most European countries, as well as in the United States, Canada, Australia, New Zealand, and several Asian countries [2]. However, childhood cancer survivors often experience long-term adverse health effects [1,2,3] and, among them, an increased risk of developing cancer later in life compared with individuals of similar age in the general population, due to both host factors and cancer treatments [4,5,6,7]. Several studies have shown that the risk of developing a second malignant neoplasm (SMN) within 3 or 5 years after diagnosis is between 3 and 15 times higher than in the general population, and that the cumulative risk at 20 years ranges from 2% to 12% [8,9]. However, this risk may vary over time due to changes in therapeutic strategies. Furthermore, although the main risk factor for a second cancer is treatment, the risk may also vary according to sex, age at first diagnosis, and genetic predisposition [8,9,10]. In the survivor population, the incidence of SMNs does not appear to stabilize over time [11,12,13,14,15]. Because most children have had limited exposure to environmental carcinogens and are expected to survive for many years after treatment, they provide a unique opportunity to study the mechanisms by which chemotherapy agents and radiation may induce carcinogenesis [16]. These considerations highlight the importance of ensuring lifelong follow-up of childhood cancer survivors. Most available evidence is derived from studies restricted to SMNs diagnosed at least 5 years after initial diagnosis [17]. To our knowledge, this study provides the first comprehensive population-based assessment of the risk of SMNs among childhood cancer survivors in Spain. In this study, we present the incidence of childhood cancer for the period 2015–2019, five- and ten-year survival for childhood cancer between 1990 and 2019, and the incidence of second cancers among individuals diagnosed with childhood cancer between 1990 and 2009 in Spain. We also report on the most common SMNs occurring up to 20 years after the initial diagnosis. 2. Materials and Methods 2.1. Study Design and Data Sources In this retrospective population-based cohort cancer registry study, all Spanish population-based cancer registries belonging to the Spanish Network of Cancer Registries (REDECAN) were invited to participate. Twelve registries participated, covering 14 provinces and two islands. Three independent analyses were performed: one on the incidence of childhood cancer (0 to 14 years) for the period 2015–2019, another on five- and ten-year survival of childhood cancer for the periods 1990–1999 and 2000–2009, and finally, one on the risk of developing SMNs among individuals diagnosed with childhood cancer during the period 1990–2009 and the sub-periods 1990–1999 and 2000–2009. Table A1 (Appendix A) shows the registries included in each analysis, as well as the corresponding periods covered. In 2000, the proportion of the Spanish child population (ages 0–14) covered by these registries was 31.5%, increasing to 32.2% in 2017. The 0–14 age group represented 14.8% of all ages in 2000 and 14.9% in 2017. The study on the risk of SMNs could only include data from general population registries (of all ages) with data from the period 1990–2009, since it analyzed the risk of secondary neoplasms 20 years after the first cancer diagnosis. All registries used the 3rd edition of the International Classification of Diseases for Oncology [18] for coding tumor site, morphology, behavior, multiple primary tumors, and basis of diagnosis. Tumors were classified centrally according to the 3rd edition of the International Classification of Childhood Cancer (ICCC-3) [19]. This study includes all malignant tumors of any site, as well as intracranial and intraspinal tumors of benign and uncertain behavior diagnosed before the age of 15 in the study populations. SMNs were defined as neoplasms occurring at a different anatomical site that did not represent direct spread or metastases of the primary neoplasm, or neoplasms on the same site with a different histological type, and they were selected based on the International Rules for Multiple Primary Cancers of 2004 [20]. Cancers diagnosed after the diagnosis of an SMN were not included in the analysis. SMNs diagnosed within two months of the first cancer were not excluded as it was assumed that most childhood cancers detected shortly after a first diagnosis would have been detected later regardless. Cancer data included individual-level records with information on the following variables: sex, age, date of incidence, tumor sequence (i.e., the numerical order of occurrence of the neoplasm), site, morphology, behavior, most valid basis of diagnosis, data of last follow-up, and vital status. Population estimates as of July 1 of each year during the study period for each province or island were obtained from the National Institute of Statistics (INE) [21]. Table 1 shows the participating registries, as well as the territory (province/s or island/s) covered by each of them, the population covered in 2000 and in 2017, the number of childhood cancers diagnosed by period, the percentage of cases diagnosed only by death certificate (%DCO) and the percentage of cases with morphological verification (%MV) during the period 2015–2019. DCO cases correspond to tumors of groups I and III. Data were obtained and analyzed from de-identified individual records from the Spanish Network of Cancer Registries (REDECAN) joint database. 2.2. Procedures All cases were extracted from the REDECAN joint database, which is systematically evaluated for data quality. All questionable cases and issues raised were referred to the contributing registries with a request for correction or clarification. This iterative process resulted in an improvement in the overall quality of the data included in the analyses. Table 1 shows two quality indicators for each registry for the period 2015–2019: the proportion of morphologically verified cases and the proportion of cases registered solely from the death certificate. 2.3. Statistical Analysis 2.3.1. Incidence Analysis To estimate the recent incidence of childhood cancer in Spain, we calculated the absolute number of incident cases (cases) and the age-standardized incidence rates (ASIRw) using the World Standard Population [22] for children aged 0–14 years (Table A2—Appendix A) by sex, expressed per million child-years, for the period 2015–2019. We calculated the incidence sex ratios by dividing the number of incident cases in boys by the number of incident cases in girls. 2.3.2. Survival Analysis We calculated 5-year and 10-year age-adjusted observed survival and their confidence intervals (95% CI), which in children corresponds very closely to relative survival since competing risks of death are negligible. Survival for the periods 1990–1999 and 2000–2009 was estimated from all cases diagnosed during these periods, irrespective of the length of follow-up, using the complete survival approach because almost all children had been followed up for at least 10 years by 31 December 2019. Survival estimates were calculated with the Kaplan–Meier method. In the survival analyses, cases registered solely from the death certificate and cases diagnosed incidentally by autopsy were excluded. To ensure comparability between sexes and time periods, and with European figures in survival analyses, we standardized according to the age distribution of all European children diagnosed with cancer using the same weights as those used by Botta et al. [23] in four age classes (<1 year, 1–4 years, 5–9 years and 10–14 years) (Table A3—Appendix A). We calculated survival for all tumors as a whole and for 15 specific categories of ICCC-3: acute lymphoid leukemias (ICCC category Ia), acute myeloid leukemias (Ib), Hodgkin lymphoma (IIa), non-Hodgkin lymphoma except Burkitt lymphoma (IIb), Burkitt lymphoma (IIc), CNS and miscellaneous intracranial and intraspinal neoplasms (III), ependymomas and choroid plexus tumor (IIIa), astrocytomas (IIIb), intracranial and intraspinal embryonal tumors (IIIc), neuroblastoma and ganglioneuroblastoma (IVa), retinoblastoma (V), nephroblastoma and other nonepithelial renal tumors (VIa), osteosarcomas (VIIIa), Ewing tumor and related sarcomas of bone (VIIIc), and rhabdomyosarcomas (IXa). Non-melanoma skin cancers were not included because most cancer registries do not register these malignant neoplasms. 2.3.3. Risk Analysis of Developing a Second Cancer The standardized incidence ratio (SIR) was calculated as the ratio of the observed number of SMNs to the number expected if patients in the cohort had the same cancer rates as the general reference population. The observed number of cases included all SMNs diagnosed in each cohort (by sex and cancer type) during each defined time period. The expected number of cases was calculated by multiplying the cumulative observed person-years by the incidence rates for cancer site, sex, five-year age group, and calendar year in the general population. The rates of the general population were obtained from the population-based cancer registries that participated in the study. In each patient, person-years at risk were defined as the period between the first childhood cancer diagnosis and the date of the second cancer diagnosis, the date of death, or the date of end of follow-up, whichever occurred first. The SIR was calculated by sex, by period of the first diagnosis of childhood cancer (1990–1999, 2000–2009 and 1990–2009) and by time between the first and second cancers (<1 year, 1–4 years, 5–9 years and 10–19 years) for all tumors as a whole. The calculation for two different periods (1990–1999 and 2000–2009) was performed to observe possible differences in risk over time. The SIR was also calculated based on the type of the first tumor (12 groups of the ICCC-3) for the 20-year period between the first and second cancer diagnoses, by sex. Finally, the SIR was also calculated based on the type of SMN according to 25 specific ICD-10 categories (lip, oral cavity and pharynx (C00-14), esophagus (C15), stomach (C16), colon (C18), rectum (C19–C21), liver (C22), gallbladder and biliary tree (C23–C24), pancreas (C25), larynx (C32), trachea, lung and bronchus (C33–C34), skin melanoma (C43), breast (C50), cervix uteri (C53), corpus uteri (C54), ovary (C56), prostate (C61), testis (C62), kidney (C64), urinary bladder (C67, D09.0, D41.4), brain and central nervous system (C70–C72), thyroid (C73), Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82–C86,C88), myeloma (C90) and leukemia (C91–C95)), and an “Other” category covering all remaining malignant tumor types, for the 20-year period between the first and second cancers and by sex. Non-melanoma skin cancers were not included because most cancer registries do not register these malignant neoplasms. We included all secondary cancers, regardless of the time elapsed between the first and second cancers. The assumption that the observed number of SMNs follows a Poisson distribution was used to calculate 95% confidence intervals (95% CIs). Results are considered statistically significant if the 95% CI does not include 1. The excess absolute risk (EAR) was calculated by subtracting the expected number of SMNs from the observed number of SMNs and dividing the difference by the person-years at risk, expressed as the number in excess (or deficit) by 10,000 person-years at risk. Finally, we calculated the observed age-specific incidence rates of SMNs in the childhood cancer cohort and compared them with the age-specific incidence rates of the general population covered by the cancer registries in Spain. All the analyses were computed using R software (version 4.5) [24]. 3. Results 3.1. Incidence A total of 31.56% of the childhood Spanish population aged 0–14 years (contributing 10,942,347 person-years) was covered by the registries included in the incidence calculations for the period 2015–2019 (Table 1 and Table A1—Appendix A). During this quinquennium, 1910 childhood tumors were diagnosed in the population covered by this study. The ASIRw of childhood cancer in Spain during 2015–2019 was 181.3 cases per million person-years, with higher rates observed in boys (192.5) than in girls (170.1). The sex ratio was 1.20. Leukemias were the ICCC-3 group with the highest incidence (53.4), followed by CNS tumors (45.2), lymphomas (23.7), and neuroblastoma (13.1). Table 2 shows the incidence of the 12 ICCC-3 groups by sex. 3.2. Survival The 5-year age-standardized observed survival rate for all cancers and both sexes combined increased significantly from the period 1990–1999 (74.1; 95% CI: 72.5–75.8) to the period 2000–2009 (77.8; 95% CI: 76.4–79.3). In boys these values were 72.3 and 75.9, and in girls 76.5 and 80.4. The 10-year survival rates also increased between the two periods: 71.3 and 75.5 in both sexes combined, 69.4 and 73.6 in boys, and 73.9 and 78.0 in girls (Table 3 and Figure 1 and Figure 2). For both sexes combined for the period 2000–2009, the highest 10-year survival rate was observed for retinoblastoma (98.9), followed by Hodgkin lymphomas (95.0), nephroblastoma and other nonepithelial renal tumors (90.3), Burkitt lymphomas (83.9), non-Hodgkin lymphomas (83.5), lymphoid leukemias (81.0) and astrocytomas (80.5). Rates below 80% were observed for neuroblastoma and ganglioneuroblastoma (69.7), CNS and miscellaneous intracranial and intraspinal tumors (63.5), rhabdomyosarcomas (62.3), and acute myeloid leukemias (60.2). The lowest rates corresponded to osteosarcomas (54.3), Ewing tumor and related bone sarcomas (51.7), ependymomas and choroid plexus tumor (51.1), and intracranial and intraspinal embryonal tumors (44.0) (Table 3). Between 1990–1999 and 2000–2009, 5-year survival rates increased significantly by an average of 3.7 percentage points for all cancers combined. By tumor type, only acute lymphoblastic leukemia showed a significant increase, whereas the remaining cancer types showed non-significant increases (0.6–10.0%), except for three that decreased: Burkitt lymphoma (−0.5%), osteosarcomas (−7.8%), and rhabdomyosarcomas (−6.8%). Between 1990–1999 and 2000–2009, 10-year survival rates increased by an average of 4.2 percentage points for all cancer types combined. Acute lymphoblastic leukemias, Hodgkin lymphomas and non-Hodgkin lymphomas showed significant increases. Across the three most common ICCC-3 groups combined (leukemias, lymphomas, and CNS tumors) survival rates increased by 5.2 percentage points (Table 3). 3.3. Risk of Developing a Second Malignant Neoplasm Table A4 shows the characteristics of childhood cancers included in the second neoplasm risk study, by period. Of the 3834 children under 15 years of age diagnosed with cancer during 1990–2009, 62 (1.6%) developed an SMN during 48,964.01 person-years of follow-up (median follow-up, 15.15 years; interquartile range [IQR], 4.51–20.00 years). The mean time between first and second diagnoses was 12.29 years (IQR, 7.70–18.25 years) for patients diagnosed with a first childhood cancer between 1990 and 1999 and 7.85 years (IQR, 4.11–11.29 years) for patients diagnosed with a first childhood cancer between 2000 and 2009. The mean time between the first and second diagnoses in the second decade was shorter because patients diagnosed in the second decade had a shorter follow-up time (Table A4—Appendix A). For both sexes combined, the SIR for developing an SMN among individuals with a first childhood cancer diagnosed between 1990 and 2009 was 5.67 at 20 years after first diagnosis. The relative risk was 12.44 during the first year, 5.99 between years 1 and 4, 4.05 between years 5 and 9, and 5.60 between years 10 and 19 after first diagnosis. These values were higher, although not statistically significant, for those diagnosed in 2000–2009 than for those diagnosed in 1990–1999 (Table 4). Likewise, these risk values were higher, although not statistically significant, in women than in men 20 years after first diagnosis (6.34 versus 5.15), whereas they were lower in women during the first year after first diagnosis (4.51 vs. 17.60). Similar patterns were observed in the ten-year periods of first diagnosis 1990–1999 and 2000–2009 (Table 4). The EAR 20 years after the first diagnosis of childhood cancer was 10.43 per 10,000 person-years at risk. The excess was higher, although not statistically significant, in women (11.44) than in men (9.60), and in the 2000–2009 period group (12.04) than in the 1990–1999 period group (9.03) (Table 4). According to age at first cancer diagnosis, all age groups showed significantly elevated SIRs: 6.30 for ages 0–4 years, 5.19 for ages 5–9 years, and 5.47 for ages 10–14 years (Table 5). The risk of developing an SMN 20 years after the diagnosis of a childhood cancer varied according to the ICCC-3 group of the first childhood cancer (Table 6). Seven ICCC-3 groups showed significantly elevated SIRs: other malignant epithelial neoplasms and malignant melanomas (7.52), CNS tumors (SIR = 7.35), bone tumors (6.87), lymphomas (6.13), soft tissue sarcomas and other extraosseous sarcomas (6.12), neuroblastoma (6.02) and leukemias (4.91). The ICCC-3 groups with the highest EAR per 10,000 person-years were: other malignant epithelial neoplasms and malignant melanomas (18.46), bone tumors (16.63), CNS tumors (14.02), lymphomas (13.56), and soft tissue sarcomas and other extraosseous sarcomas (11.84). By sex, the statistically significant SIRs were higher in women for leukemias (6.28 vs. 3.93), lymphomas (7.87 vs. 5.25), CNS tumors (9.05 vs. 5.74) and other malignant epithelial neoplasms and malignant melanomas, and in men for bone tumors and soft tissue sarcomas and other extraosseous sarcomas (Table 6). The most common types of SMNs with a statistically significant elevated SIR at 20 years after diagnosis were thyroid carcinomas (n = 12, 19%, SIR = 14.14), leukemias (n = 11, 18%, SIR = 7.07), bone sarcomas (n = 10, 16%, SIR = 16.25), soft tissue sarcomas (n = 6, 10%, SIR = 13.98), brain and central nervous system tumors (n = 5, 8%, SIR = 5.14) and breast carcinomas (n = 3, 5%, SIR = 8.02). By sex, significantly increased SIRs were observed in men for thyroid (33.37), soft tissue (11.73), bone (10.20) and leukemias (8.27), and in women for soft tissue (17.29), breast (8.02), thyroid (7.82) and bone (6.86) (Table 7). Finally, Figure 3 shows the age-specific observed incidence rates of SMNs in the study cohort and the corresponding incidence rates in the general population covered by cancer registries in Spain. Across all five-year age groups, the observed rates were clearly higher than expected. 4. Discussion 4.1. Incidence Registration of non-malignant CNS tumors may vary across registries, which may lead to a slight underestimation of the incidence of all cancers combined. The ASIRw of childhood cancer for both sexes combined in Spain during the period 2015–2019 was 181.3 per million person-years, a figure slightly higher than that reported by Steliarova-Foucher et al. for Southern Europe during 2001–2010 (170.8) [25]. In our study, ASIRw was higher in boys than in girls, with a sex ratio (SR = 1.13) similar to that reported globally (SR = 1.17) [25]. Sex-specific incidence varied by diagnostic group, with neuroblastomas, germ cell and gonadal tumors, and epithelial tumors being more common in girls than in boys. In Spain, leukemias, followed by CNS tumors, and lymphomas, had the highest ASIRw, consistent with the pattern observed in most regions worldwide, except in Africa, where lymphomas are more common than CNS tumors [25]. The remaining groups followed a similar distribution to that reported for Southern Europe [25] except for bone tumors (group VIII) and other malignant epithelial neoplasms (group XI), which rank seventh and eighth in Southern Europe, compared with eighth and seventh in Spain. 4.2. Survival The five-year survival rate for all childhood cancer combined in Spain during 2000–2009 was 77.8% (95% CI: 76.4–79.3), representing a significant increase of almost four percentage points compared with 1990–1999 (74.1%; 95% CI: 72.5–75.8). Significant progress over time was observed for lymphoid leukemias, the most common childhood cancer. Survival remained stable for the other tumor types, although non-significant increases were observed in most of them, including acute myeloid leukemias, Hodgkin lymphomas, non-Hodgkin lymphomas (except Burkitt lymphomas), CNS tumors, neuroblastomas, retinoblastomas, nephroblastomas, and Ewing sarcomas. Only Burkitt lymphomas, osteosarcomas, and rhabdomyosarcomas showed a decrease in survival rates, although these changes were not statistically significant. The 5-year survival rate for childhood cancer in Spain during 2000–2009 was 3.5 percentage points lower than that reported for Europe overall and 3.3 percentage points lower than that reported in Spain during 2010–2014 [23], suggesting that survival rates continue to improve. The increase in 5-year survival rates for all childhood cancer combined in Spain between the 1990s and 2000s is similar to that observed in Europe between 2004–2006 and 2010–2014, where rates increased from 78% to 81%. In Europe, significant improvements in survival over time were observed for almost all cancer types, although rates remained stable for Burkitt lymphoma, non-Hodgkin lymphomas, osteosarcomas, Ewing sarcoma, and rhabdomyosarcomas. Ten-year survival rates also increased significantly between the 1990s and the 2000s. For all tumors combined, the rate rose from 71.3% to 75.5%. The cancer types with the largest increases were lymphoid leukemias (72.8% to 81.0%), Hodgkin lymphomas (88.7% to 95.0%), and non-Hodgkin lymphomas (except Burkitt lymphomas) (72.3% to 83.5%). Although survival for acute myeloid leukemias increased by 10 percentage points (from 50.3% to 60.2%), this change was not statistically significant. 4.3. Risk of Developing a Second Malignant Neoplasm To the best of our knowledge, this is the first study to analyze the risk of developing SMNs after childhood cancer in Spain, using a population-based cohort of 3834 childhood cancer survivors diagnosed between 1990 and 2009, and followed for up to 20 years. Most studies on secondary neoplasms exclude cancers diagnosed within the first 2 months [15,26], 6 months [27,28], 3 years [29,30,31], or 5 years [16,17,32,33,34,35,36] after the initial diagnosis to minimize selection bias, i.e., the misclassification of progression or recurrence as an SMN. As different studies apply varying exclusion criteria, this decision is inherently subjective. In our study, we included these cancers to estimate the overall risk of developing SMNs, as a substantial proportion of second cancers occur within the first few years after the first diagnosis. Excluding these cases would therefore lead to an underestimation of the absolute risk. Furthermore, the high quality of the registries allowed us to rely on the data regarding SMN. Accordingly, the follow-up period for SMNs began at the date of diagnosis of first malignancy as per Olsen and colleagues in the Nordic countries [7,14]. This methodology provides a more comprehensive estimation of the risk of developing SMNs, regardless of the underlying causes. The results of this study show an overall SIR of 5.67 for SMNs 19 years after the first cancer diagnosis, with similar values for both sexes. Comparison of SIR values with those reported in other studies is challenging, as they are influenced not only by patient characteristics, environmental factors and treatment of the first cancer, but also by the calendar period of the initial diagnosis, the inclusion criteria for subsequent tumors, the age range at the first diagnosis (0–14 or 0–19 years), the duration of follow-up, the attained age during follow-up, and the study design. These factors partly explain why reported SIRs in childhood cancer survivors vary widely, ranging from 3 to 20 [11,14,17,27,31,32,36,37]. The SIRs for SMNs varied slightly by the calendar period of first childhood cancer diagnosis, with the highest risks observed in children diagnosed during the most recent period (2000–2009) compared with 1990–1999. Although differences in risk were observed across all follow-up intervals (0–, 1–4, 5–9, and 10–19 years), these differences between the two periods were not statistically significant, likely due to the small number of cases. The increase in SIR occurred despite advances in radiotherapy during the 1990s and 2000s; this is consistent with previous findings suggesting a role of chemotherapeutic agents in the etiology of second cancers [14]. Indeed, since the late 1990s, chemotherapy has been intensified, and radiotherapy treatments have been carried out with higher doses in some cancers. In the 1990s, treatments were less intensive, and patients with relapse had poorer survival. Subsequently, relapses began to be actively treated, increasing treatment intensity and, consequently, the risk of SMNs. However, we cannot rule out that part of the observed excess may also reflect improvements in diagnostic and registration procedures (e.g., neuroimaging studies). Previous studies showed that relative risk of SMNs decreases over time since the first cancer diagnosis, although it remains elevated decades after childhood cancer diagnosis [7,12,15,30,31,32,38]. In our study, the SIR decreased during the first 9 years after the first cancer diagnosis; however, the SIR between 10 and 19 years (5.60) was slightly higher than between 5 and 9 years, although this difference was not statistically significant. This pattern is consistent with the persistence of elevated relative risk over decades, suggesting long-term carcinogenic effects of childhood cancer treatment [14]. Olsen and colleagues also suggested that the observed reduction in relative risk with increasing age may reflect age-related increases in background cancer incidence rather than a true reduction in the carcinogenic effects of childhood cancer treatment. Conversely, in large studies with long-term follow-up, the EAR attributable to childhood cancer survival status increases over time since the first cancer diagnosis. Therefore, the number of patients with SMNs continues to increase, driven not only by the growing number of long-term survivors, but also by the progressive aging of this population [14]. In our study, although EAR decreased during the first years after childhood cancer, the EAR during the first nine years (7.85; 95% CI: 4.65–12.09) is lower than that observed between 10 and 19 years (14.35; 95% CI: 8.97–21.31). Young age at first cancer diagnosis has been associated with a higher relative risk of developing SMNs [7,12,15,26,28,31,32,39]. In our study, elevated SIRs were observed across all three age groups. The SIR for children aged 0–4 years (6.30; 95% CI: 3.94–9.55) was only slightly higher than for those diagnosed at ages 5–9 and 10–14 years, although this difference was not statistically significant. Despite the small number of cases, the SIR for SMNs in our cohort was significantly elevated in seven of the twelve ICCC-3 groups by first cancer type (ranging from 4.91 for leukemias to 7.52 for other malignant epithelial neoplasms and malignant melanomas), and it was greater than 1.0—although not statistically significant—in three additional groups. ICCC-3 Groups I to IV (leukemias, lymphomas, CNS tumors and neuroblastomas) accounted for 69% of the SMNs. In absolute terms, the most common SMN types according to ICD-10 were thyroid (n = 12), leukemias (n = 11), bone (n = 10), soft tissue (n = 6), central nervous system (n = 5), and breast (n = 3). The highest relative risks were observed for bone sarcomas (SIR = 16.74; 95% CI: 7.74–30.0), thyroid carcinomas (SIR = 14.14; 95% CI: 7.27–24.77), and soft tissue sarcomas (SIR = 13.98; 95% CI: 5.03–30.63). These three tumor types have also been reported to show a high SIR in multiple studies [14]. Significant elevations were also observed for breast cancer, other and unspecified malignancies, leukemias, and CNS and miscellaneous intracranial and intraspinal tumors. The main strength of this study lies in the use of recent, high-quality population-based data on childhood cancer incidence, survival and the risk of developing SMNs in Spain. The use of high-quality cancer registry data to identify and verify SMNs resulted in a virtually complete and unbiased ascertainment, minimizing potential selection biases due to nonparticipation, loss to follow-up, or differential reporting across treatment centers. In addition, follow-up through data linkage reduced loss to follow-up over time. One limitation of this study is the relatively small number of cases in some risk categories, which limits a meaningful analysis of certain types of second cancers. Potentially better ascertainment of patients with SMNs compared with those with a single tumor may have introduced surveillance bias, leading to an overestimation of relative risks. However, screening programs for asymptomatic adult childhood cancer survivors have not been common in Spain; therefore, the impact of this bias is likely to be limited. Another limitation of the study is that we do not have access to information on SMNs in individuals who were diagnosed with childhood cancer in a region with a population-based registry who subsequently emigrated from that region. This could lead to a slight underestimation of the risk of SMNs. Finally, for more than 50 years, SMNs in childhood cancer survivors have been recognized as a late sequela of treatment [40], and studies have shown substantial heterogeneity in relative risks according to treatments, with the highest risks observed in patients exposed to both radiotherapy and chemotherapy [31]. A major limitation of this study is the lack of treatment information (e.g., patients who received radiotherapy vs. the ones who did not), which precludes direct assessment of treatment-related risks. Nevertheless, the use of high-quality population-based data provided by cancer registries ensures robust and generalizable estimates. And although we were unable to evaluate them in our study, we believe that radiotherapy (especially for breast and thyroid cancers), some types of chemotherapy (e.g., topoisomerase II inhibitors, alkylating agents) and genetic factors are the main factors in the development of SMNs. 5. Conclusions In the 2000s, the 5-year survival rate for childhood cancer in Spain approached 80%, but survivors remained at high risk of developing second cancers for at least 20 years after the first diagnosis. These findings highlight the need to balance treatment efficacy with long-term safety and to improve survivorship follow-up strategies. Reducing treatment-related toxicity while maintaining survival gains should be a key priority in pediatric oncology.